Lantern pharma reports fourth quarter and fiscal year 2021 financial results and operational highlights

Dallas, march 10, 2022 /prnewswire/ -- lantern pharma inc. (nasdaq: ltrn), a clinical stage biopharmaceutical company using its proprietary radr® artificial intelligence ("a.i.") and machine learning (ml) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced financial results and operational highlights for the fourth quarter and fiscal year ended december 31, 2021.
LTRN Ratings Summary
LTRN Quant Ranking